Literature DB >> 9802737

Lack of agreement between the World Health Organization Category of impaired glucose tolerance and the American Diabetes Association category of impaired fasting glucose.

F J Gómez-Pérez1, C A Aguilar-Salinas, J C López-Alvarenga, J Perez-Jauregui, L E Guillen-Pineda, J A Rull.   

Abstract

OBJECTIVE: To study the concordance between the 1997 American Diabetes Association (ADA) impaired fasting glucose (IFG) category with the World Health Organization (WHO) impaired glucose tolerance (IGT) status in a population with a high prevalence of diabetes. RESEARCH DESIGN AND METHODS: We analyzed the oral glucose tolerance tests (OGTTs) carried out at the Instituto Nacional de la Nutrición Salvador Zubiran (INNSZ) central laboratory from June to December 1997. We included patients with fasting plasma glucose (FPG) between 60 and 160 mg/dl. The results from the glucose tolerance test were selected as the gold standard.
RESULTS: Among the 1,802 glucose tolerance test results available for analysis, 1,706 fulfilled the requirements to be included. Diabetes and IGT were remarkably more frequently diagnosed when the WHO criteria were applied. The new ADA criteria failed to diagnose 69% of WHO diabetic patients and the vast majority of WHO glucose-intolerant subjects. Using the new criteria, 82% were considered normal. Of the IFG subjects, 39% were classified as diabetic and 23% were normal according to the 2-h postchallenge glucose values. Only 37% of the IFG patients were, in fact, glucose intolerant according to the WHO criteria.
CONCLUSIONS: Our results clearly show that the 1997 ADA criteria are less sensitive for diagnosing diabetes than OGTT-based WHO criteria. Even more important, there is poor agreement between the WHO category of IGT and the ADA category of IFG.

Entities:  

Mesh:

Year:  1998        PMID: 9802737     DOI: 10.2337/diacare.21.11.1886

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  6 in total

1.  Abnormal Fasting Glucose Increases Risk of Unrecognized Myocardial Infarctions in an Elderly Cohort.

Authors:  Richard Brandon Stacey; Janice Zgibor; Paul E Leaverton; Douglas D Schocken; Jennifer A Peregoy; Mary F Lyles; Alain G Bertoni; Gregory L Burke
Journal:  J Am Geriatr Soc       Date:  2018-10-09       Impact factor: 5.562

2.  New ADA criteria in the Korean population: fasting blood glucose is not enough for diagnosis of mild diabetes especially in the elderly.

Authors:  Y H Choi; Y B Ahn; K H Yoon; M I Kang; B Y Cha; K W Lee; H Y Son; S K Kang
Journal:  Korean J Intern Med       Date:  2000-12       Impact factor: 2.884

3.  Comparison of glucose tolerance categories in the Korean population according to World Health Organization and American Diabetes Association diagnostic criteria.

Authors:  K S Park; Y J Park; S W Kim; C S Shin; D J Park; J J Koh; S Y Kim; N K Kim; H K Lee
Journal:  Korean J Intern Med       Date:  2000-01       Impact factor: 2.884

4.  Predictive Power for Type 2 Diabetes Mellitus using Dynamic Change of Metabolic Syndrome, Dynamic Change of Fasting Plasma Glucose, Metabolic Syndrome and Fasting Plasma Glucose.

Authors:  Hui Zhou; Chen Yang; Chen Dong; Zhirong Guo; Xiaoshu Hu; Yong Xu; Zhengyuan Zhou
Journal:  Iran J Public Health       Date:  2014-04       Impact factor: 1.429

5.  Serum IRAP, a Novel Direct Biomarker of Prediabetes and Type 2 Diabetes?

Authors:  Candice Trocmé; Nicolas Gonnet; Margaux Di Tommaso; Hanen Samouda; Jean-Luc Cracowski; Claire Cracowski; Stéphanie Lambert-Porcheron; Martine Laville; Estelle Nobécourt; Chiraz Gaddhab; Allan Le Lay; Torsten Bohn; Christine Poitou; Karine Clément; Fahd Al-Mulla; Milad S Bitar; Serge P Bottari
Journal:  Front Mol Biosci       Date:  2021-02-16

6.  Predicting glucose intolerance with normal fasting plasma glucose by the components of the metabolic syndrome.

Authors:  Dee Pei; Jiunn-Diann Lin; Du-An Wu; Chang-Hsun Hsieh; Yi-Jen Hung; Shi-Wen Kuo; Ko-Lin Kuo; Chung-Ze Wu; Jer-Chuan Li
Journal:  Ann Saudi Med       Date:  2007 Sep-Oct       Impact factor: 1.526

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.